CC Diagnostics
PrivateLast Round
Grant
Sep 23, 2025
Total Funding Raised
$648,000
Momentum
Top 1%
of companies Caplight tracks
Company Overview
CC Diagnostics operates in Healthcare & Life Sciences and is based in Groningen. Its latest recorded funding round was a Grant round in September 2025.
CC Diagnostics is a biotechnology company that develops PCR-based diagnostic solutions for the early detection of cervical cancer.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CC Diagnostics Comparables
Compare CC Diagnostics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Epitype GmbH | 88% | |
| Self-screen B.V. | 87% | |
| Predica Diagnostics | 85% |
For institutional investors. Book with your work email.
CC Diagnostics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 23, 2025 | ||||
| Accelerator | May 13, 2024 | ||||
| Grant | May 1, 2023 | ||||
| Seed | Jul 17, 2018 | ||||
| Debt | Jul 17, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
CC Diagnostics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Carduso Capital | Seed |
| Tech4Eva | Accelerator |
| Samenwerkingsverband Noord-Nederland | Grant |
| Netherlands Enterprise Agency | Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 5, 2026
Won the MedTech Twente NextGen Award for cancer detection technology.
- Sep 24, 2025
Received the LIFE Science Innovation Award 2025.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_awardNov 5, 2026
At the TechMed event hosted on the University of Twente campus, CC Diagnostics receives the MedTech Twente NextGen Award and €10,000 from MedTech Twente for its non-invasive cervical cancer detection technology and its potential for high impact.
For institutional investors. Book with your work email.
CC Diagnostics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about CC Diagnostics's valuation, stock price, and market status.
Is CC Diagnostics a public or private company?
CC Diagnostics is a private company.
What is the current stock price of CC Diagnostics?
CC Diagnostics is a private company, so its shares have no public market price. Caplight tracks CC Diagnostics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CC Diagnostics worth (valuation)?
Valuation information for CC Diagnostics is not publicly available.
Can I buy CC Diagnostics stock?
CC Diagnostics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CC Diagnostics's last funding round?
CC Diagnostics's most recent funding round was Grant on September 23, 2025.
Who are the main investors in CC Diagnostics?
Key investors in CC Diagnostics include Carduso Capital.
Will CC Diagnostics IPO soon?
No public IPO plans have been announced for CC Diagnostics.
How can I track CC Diagnostics secondary market activity?
Caplight tracks bids, offers, and trades in CC Diagnostics's shares on secondary markets.